5 November
2024
Aptamer
Group plc
("Aptamer", the "Company" or the "Group")
Posting
of Annual Report and Accounts and Notice of Annual General
Meeting
Aptamer Group plc (AIM:
APTA), the developer of
novel Optimer® binders to enable innovation in
the life sciences industry, today announces that the Annual Report
and Accounts for the year ended 30 June 2024 and Notice of its 2024
Annual General Meeting (AGM) were posted to shareholders
today. These documents are available on the company's website
at https://aptamergroup.com/.
Aptamer will host its AGM at 10:00
GMT on 29 November 2024 at Windmill House, Innovation Way, York,
YO10 5BR. The AGM will be held in person only and there will
be no new information presented at the meeting.
The results of voting on all
resolutions at the AGM will be announced to the London Stock
Exchange and the full results of the voting published on the
Company's website, as soon as practicable after the conclusion of
the AGM.
- Ends
-
For further information, please
contact:
|
Aptamer Group plc
Andrew Rapson, Chief Financial Officer
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Adam Dawes
|
+44 (0) 20 3368 3550
|
|
Turner
Pope Investments
(TPI) Limited - Broker
James Pope /
Andrew Thacker
|
+44 (0) 20 3657 0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer
Group develops custom affinity binders through its proprietary
Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer® platform.
Optimer® binders are
oligonucleotide affinity ligands that can function as an antibody
alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer® binders are engineered to
address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered
projects for global pharma companies, diagnostic development
companies and research institutes covering a range of targets and
applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer® technology and
processes, scientists and collaborators can make faster, more
informed decisions that support discovery and development across
the Life Sciences.